Is ANAVEX life sciences (avxl) a good stock to buy?

Anavex Life Sciences ( NASDAQ: AVXL) stock rose ~62% premarket after its oral drug ANAVEX2-73 (blarcamesine) met the main goal of a phase 2B/3 trial in patients with early Alzheimer's disease, which led Jones Research to double its price target on the shares to $80 while reiterating a Buy rating.

Is avxl stock a buy?

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review (s) in last seven days. We see that AVXL’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average.

Is avxl stock in a downtrend?

As of 2022 August 26, Friday current price of AVXL stock is 10.600$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception). Anavex Life Sciences stock price has been showing a declining tendency so we believe that similar market segments were not very popular in the given period.